Clinical pharmacology and therapeutic uses of non‐steroidal anti‐inflammatory drugs in the horse

Equine Veterinary Journal - Tập 17 Số 2 - Trang 83-96 - 1985
P. Lees1, A.J. Higgins1
1Department of Physiology, Royal Veterinary College, North Mymms, Hatfield, Hertfordshire AL9 7TA

Tóm tắt

Summary

Weak organic acids possessing anti‐inflammatory, analgesic and antipyretic properties — commonly known as aspirin‐like drugs — have been used in equine medicine for almost 100 years. These non‐steroidal anti‐inflammatory drugs (NSAIDs) may be classified chemically into two groups; the enolic acids such as phenylbutazone and carboxylic acids like flunixin, meclofenamate and naproxen. All NSAIDs have similar and possibly identical modes of action accounting for both their therapeutic and their toxic effects. They block some part of the cyclo‐oxygenase enzyme pathway and thereby suppress the synthesis of several chemical mediators of inflammation, collectively known as eicosanoids. The available evidence indicates that some of the newer NSAIDs have a reasonable safety margin but further studies are required. The toxicity of phenylbutazone in the horse has been investigated very thoroughly in recent years and it has been shown to cause renotoxicity and, most significantly, ulceration of the gastrointestinal tract when relatively high doses are administered. Several factors may predispose towards phenylbutazone toxicity in the horse, including breed and age, but high dosage is considered to be particularly important. The absorption into, and fate within, the body of NSAIDs are considered and particular attention is drawn to the ways in which these pharmacokinetic properties relate to the drugs' toxicity and clinical efficacy. In reviewing current knowledge of the clinical pharmacology of this important group of drugs, it is hoped to provide the clinician with a rational, scientific basis for their safe and effective use in equine practice.

Từ khóa


Tài liệu tham khảo

10.1136/vr.110.12.271

Bottoms G. D., 1981, Endotoxin‐induced hemodynamic changes in ponies: effects of flunixin meglumine, Am. J. vet. Res., 42, 1514

Burrows G. E., 1981, Therapeutic effect of phenylbutazone on experimental acute Escherichia coli endotoxemia in ponies, Am. J. vet. Res., 42, 94

Chay S., 1982, The pharmacology of nonsteroidal anti‐inflammatory drugs in the horse: flunixin meglumine (Banamine), Equine Pract., 4, 16

Conner G. H., 1973, Arquel (Cl‐1583) A new non‐steroidal anti‐inflammatory drug for horses, Proc. Am. Ass. equine Pract., 19, 81

Davis L. E., 1972, Species differences in biotransformation and excretion of salicylate, Am. J. vet. Res., 33, 1253

Davis L. E., 1973, Biotransformation and pharmacokinetics of salicylate in newborn animals, Am. J. vet. Res., 34, 1105

Dun F., 1895, Veterinary Medicines, Their Actions and Uses, 601

Dunavant M. L.andMurray E. S.(1975)Clinical evidence of phenylbutazone‐induced hypoplastic anemia.Proc. 1st Int. Symp. Equine Hematol.. pp353–355.

Fessler J. F., 1982, Endotoxin‐induced change in hemograms, plasma enzymes and blood chemical values in anesthetized ponies: effects of flunixin meglumine, Am. J. vet. Res., 43, 140

Flower R. J., 1974, Drugs which inhibit prostaglandin biosynthesis, Pharmacol. Rev., 26, 33

Gabel A. A., 1977, Phenylbutazone in horses: a review, J. equine Med Surg., 1, 221

Gabriel K. L., 1962, Phenylbutazone: short‐term versus long‐term administration to thoroughbred and standardbred horses, J. Am. vet. med. Ass., 140, 337

10.1111/j.2042-3306.1981.tb03472.x

Gunson D. E., 1983, Renal papillary necrosis in horses, J. Am. vet. med. Ass., 182, 263

10.1177/030098588302000512

Hamm D., 1978, Continuous administration of naproxen to the horse during training, J. equine Med. Surg., 2, 125

Higgins A. J., 1983, Phenylbutazone inhibition of prostaglandin E2 production in equine acute inflammatory exudate, Vet. Rec., 113, 622

10.1111/j.2042-3306.1984.tb01893.x

Higgins A. J., 1984, Influence of phenylbutazone on eicosanoid levels in equine acute inflammatory exudate, Cornell Vet., 74, 198

10.1016/0006-2952(79)90651-8

10.1016/0098-2997(81)90007-8

10.1111/j.2042-3306.1972.tb03881.x

Houdeshell J. W., 1977, A new nonsteroidal anti‐inflammatory analgesic for horses, J. equine Med. Surg., 1, 57

10.1111/j.2042-3306.1979.tb01360.x

10.3181/00379727-141-36911

10.1111/j.2042-3306.1977.tb03997.x

10.1111/j.1365-2885.1979.tb00361.x

Johnstone I. B., 1983, Comparative effects of phenylbutazone, naproxen and flunixin meglumine on equine platelet aggregation and platelet factor 3 availability in vitro, Can. J. comp. Med., 47, 172

10.1080/00480169.1977.34443

Jones E. W., 1978, Comparative efficacy of phenylbutazone and naproxen in induced equine myositis, J. equine Med. Surg., 2, 341

10.1016/S0034-5288(18)32589-X

10.1038/209519a0

Killian J. G. Jones E. W. Hamm D. Riley W. F.andAverkin E.(1974)The efficacy of Equiproxen (naproxen) in a unique equine myositis model.Proc. 20th Ann. Conv. Am. Ass. equine Pract.. pp201–215.

10.1016/S0034-5288(18)31876-9

Lees P., 1982, Pharmacologie, Toxicologie Vétérinaires, 159

10.1111/j.2042-3306.1983.tb01745.x

Lees P., 1983, Pharmacokinetics of phenylbutazone in Welsh Mountain ponies, AVCPT Proceedings, 7, 32

Lehmann W., 1981, Kinetik einiger analgetisch‐antiinflammatorrischer Arzneimettel in Serum und Synovia beim Pferd, Deutsche Tierarzt. Wochenschrift, 88, 218

Mackay R. J., 1983, Effects of large doses of phenylbutazone administration to horses, Am. J. vet. Res., 44, 774

Maitho T. E., 1985, Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies, J. Vet. Pharmacol. Ther.

Maylin G. A.(1974)Disposition of phenylbutazone in the horse.Proc. 20th Conv. Ass. Am. equine Pract.. pp243–249.

Meschter C. L., 1984, Vascular pathology in phenylbutazone intoxicated horses, Cornell Vet., 74, 282

10.1111/j.2042-3306.1981.tb04122.x

10.1111/j.2042-3306.1972.tb03882.x

Phillips M. W., 1980, Equine metabolism and pharmacokinetics of indomethacin, Equine Pract., 2, 45

Piperno E., 1968, Plasma and urine levels of phenylbutazone in the horse, J. Am. vet. med. Ass., 153, 195

10.1177/030098588302000602

Roberts M. C., 1981, Suspected phenylbutazone toxicity in an adult stockhorse, Aust. vet. Pract., 11, 112

10.1111/j.1365-2885.1982.tb00501.x

10.1111/j.2042-3306.1982.tb02404.x

10.1007/BF02228646

Sams R., 1979, Equine Pharmacology, 17

Scott Dunn P., 1971, A clinician's views on the use and misuse of phenylbutazone, Equine vet. J., 4, 63

Snow D. H., 1981, Non‐steroidal anti‐inflammatory agents in the horse, Vet. Rec. In Pract., 3, 24

Snow D. H., 1983, Pharmacological Basis of Large Animal Medicine, 391

10.1136/vr.105.2.26

10.1111/j.1365-2885.1981.tb00724.x

Snow D. H., 1981, Phenylbutazone toxicosis in Equidae: a biochemical and pathophysiologic study, Am. J. vet. Res., 42, 1754

10.1136/vr.112.26.602

10.1007/BF02228619

10.1098/rstl.1763.0033

10.1136/vr.110.24.554

10.1136/vr.112.26.599

Templeton C. B., 1983, Effects of flunixin meglumine on hemodynamics, hematology, prostaglandins and survival in ponies during chronic exposure to endotoxin, Fed. Proc., 42, 323

Tobin T., 1979, Pharmacology review: the nonsteroidal anti‐inflammatory drugs. 1. Phenylbutazone, J. equine Med. Surg., 6, 253

Tobin T., 1979, Pharmacology review: the non‐steroidal anti‐inflammatory drugs II. Equiproxen, meclofenamic acid, flunixin and others, J. equine Med. Surg., 6, 298

Tobin T., 1977, Drug interactions in the horse: effects of chloramphenicol, quinidine and oxyphenbutazone on phenylbutazone metabolism, Am. J. vet. Res., 38, 123

Traub J. L., 1983, Phenylbutazone toxicosis in the foal, Am. J. vet. Res., 44, 1410

Traub J. L., 1983, The uses of phenylbutazone in the horse, Comp. Cont. Ed. pract. Vet., 5, S320

Trillo M. A., 1984, Flunixin toxicity in a pony, Equine Pract., 6, 21

10.1111/j.2042-3306.1981.tb03491.x

Vane J. R., 1973, Cellular Mechanisms, 353

Vernimb G. D., 1977, Clinical studies on flunixin meglumine in the treatment of equine colic, J. equine Med. Surg., 1, 111

Vogel C. J., 1982, From firing to phenylbutazone in equine practice, Vet. Rec., 110, 523

Wanner F., 1979, Third Int. Symp. equine Med. Control

10.1136/vr.115.2.45-b

10.1038/284271a0

10.1159/000136348